Sign In
Buy ANAB
$53.36
-1.68 (-3.05%)
At Close: Jul 31, 2026
AnaptysBio: The Royalty Waterfall Is About To Reverse
12:10am, Wednesday, 29'th Jul 2026
AnaptysBio is now a focused royalty management company, with its value tied primarily to Jemperli royalties from GSK. Post-spin, ANAB operates virtually with a 95% targeted EBIT margin and over $140M
AnaptysBio (NASDAQ:ANAB) Stock Price Up 5.3% – Still a Buy?
04:02am, Sunday, 19'th Jul 2026
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) rose 5.3% during mid-day trading on Friday. The company traded as high as $56.54 and last traded at $57.00. 47,244 shares were traded during mid-day t
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer
09:31am, Tuesday, 14'th Jul 2026
GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
10:40am, Thursday, 21'st May 2026
Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
10:55am, Tuesday, 19'th May 2026
The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:55am, Thursday, 14'th May 2026
After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revi
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
04:15pm, Tuesday, 12'th May 2026
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today report
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
09:15am, Monday, 11'th May 2026
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announce
AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?
01:01pm, Wednesday, 06'th May 2026
Does AnaptysBio, Inc. (ANAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
10:41am, Tuesday, 05'th May 2026
Here is how AnaptysBio, Inc. (ANAB) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
04:15pm, Monday, 04'th May 2026
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announc
WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:06am, Tuesday, 28'th Apr 2026
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:02am, Monday, 27'th Apr 2026
AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?
09:20am, Monday, 27'th Apr 2026
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
